The global hysteroscopy procedures market size was valued at USD 4.34 billion in 2022. It is estimated to reach USD 7.64 billion by 2031, growing at a CAGR of 6.5% during the forecast period (2023–2031).
Hysteroscopy is a procedure that enables a surgeon to examine the interior of the uterus to diagnose and treat abnormal bleeding. The primary purpose of hysteroscopy is to diagnose and treat abnormal uterine bleeding, excessive menstrual bleeding, irregular spotting between periods, and menopausal bleeding. During hysteroscopy, a narrow, illuminated device called a hysteroscope is placed into the vagina to inspect the cervix and uterus contents. Using operative hysteroscopy, polyps, fibroids, and adhesions can be removed.
Hysteroscopy can further be classified into types; diagnostic hysteroscopy and operative hysteroscopy. The diagnostic hysteroscopy identifies uterine structural abnormalities that may be causing abnormal bleeding. Hysteroscopy may also validate the results of other diagnostic procedures, such as an ultrasound or hysterosalpingography (HSG). An abnormality detected during a diagnostic hysteroscopy is treated during operative hysteroscopy. Hysteroscopy is regarded as a safe procedure. In less than 1% of cases involving hysteroscopy, complications occur.
The surging prevalence of gynecological disorders, such as abnormal vaginal bleeding, uterine fibroids, cervical cancer, ovarian cysts, endometriosis, and other related disorders, drives the hysteroscopy procedures market. One of the most common gynecological conditions worldwide, uterine cancer, is rising exponentially. The rising prevalence of obesity, which raises the risk of uterine cancer, is the primary cause of this increase. For instance, 66,570 new cases of uterine cancer were anticipated to be diagnosed in 2021, according to the American Cancer Society. Similarly, it was predicted that 12,940 women lost their lives to uterine cancer in 2021. As a result, the prevalence of uterine cancer has increased, leading to an increase in hysteroscopy procedures and accelerating market growth.
Another common gynecological disorder is uterine fibroids. It is a soft tumor of smooth muscle cells that forms in the uterus and can cause extreme menstrual bleeding, infertility, frequent urination, and pelvic pain. Furthermore, 25% of women experience serious issues due to uterine fibroids. For instance, according to a study published in Dove Press Ltd., the prevalence of uterine fibroid disease varies depending on the age group, from 5.4% to 23.6%. Therefore, the increasing prevalence of uterine fibroids is driving the market.
The lower risk involved in minimally invasive surgical procedures is leading to an increase in their usage. These procedures are now widely used because of how little pain is experienced after surgery and how quickly patients recover. As an illustration, hysteroscopy is linked to fewer hospitalizations, quicker recovery, and less blood loss. Additionally, less pain and an abdominal wound are experienced after hysteroscopy. As a result, the market is anticipated to expand substantially over the forecast period due to an increase in patient preference for minimally or noninvasively invasive treatments and the benefits these approaches offer.
Furthermore, several significant players make R&D investments to introduce cutting-edge, minimally invasive surgical instruments. Hysteroscopes with various high-tech features that can be customized for the intended procedure are offered on the market. As an illustration, Meditrina, Inc. introduced the Aveta Opal hysteroscope and Aveta auto resecting device in July 2021. This new launch will strengthen the company's market position, enabling it to diversify its line of products for hysteroscopic tissue resection. The advantages of these devices must be viewed collectively to raise the demand for minimally invasive procedures and fuel market expansion.
Several large companies are operating in this market, increasing competitive pricing. Hospitals and clinics in underdeveloped countries find it difficult to afford hysteroscopy devices available in the U.S. For instance, these systems utilize an adapter for hysteroscopy procedures, and total systems might cost between USD 15,000 to USD 30,000, making it expensive. Hence, these countries prefer low-cost products from local companies. In addition, local manufacturers must offer high-quality, competitively priced devices to capture a share of emerging markets. Therefore, pricing pressure on key players will probably limit the market for hysteroscopy procedures.
Additionally, the shortage of skilled and experienced surgeons to perform such advanced procedures and the lack of infrastructure in developing nations limit the adoption of hysteroscopy devices in hospital settings. To address this challenge, market players are stressing providing specific training to healthcare physicians and surgeons globally. Therefore, the factors above are anticipated to restrain market growth.
The introduction of innovative products due to the growing number of hysteroscopy procedures is expected to drive demand. Technological advancements have resulted in the development of high-definition miniature hysteroscopes, making hysteroscopy an ingenious, safe, and trusted office procedure without compromising the optical performance. Bipolar electrosurgery, endometrial ablation devices, morcellators, and tissue retrieval systems are examples of recent advancements that have transformed this procedure.
Leading companies in the industry, including Hologic, Inc., CooperSurgical, Inc., Stryker Corporation, Karl Storz GmbH, Medtronic, Delmont Imaging, and Johnson and Johnson Services, Inc., are actively engaged in R&D to manufacture cutting-edge products and are working to continuously bring technologically advanced products to market. For instance, VirtaMed introduced a certified combined mixed reality training platform for gynecological laparoscopy and hysteroscopy in February 2021.
Similarly, iCare, developed by Delmont Imaging, is an advanced hysteroscopy database management application and part of the imaging solution. It allows for direct hysteroscopy examination monitoring via private and secured Wi-Fi on an iPad Pro. As a result, such developments are likely to increase product demand, opening up opportunities for market expansion.
The global hysteroscopy procedures market is segmented by end-user.
Based on end-user, the global market is segmented into hospitals, clinics, and ambulatory surgery centers.
The hospital segment owns the highest market share and is estimated to exhibit a CAGR of 6.4% during the forecast period. The increasing incidence of diseases such as uterine fibroids, endometriosis, and gynecological cancers (ovarian, cervical, uterine, etc.) and a growing number of gynecology surgical procedures contribute to segment growth. Operative hysteroscopy is performed in hospitals to correct any abnormal condition detected during diagnostic hysteroscopy. It can be performed after diagnosis, surpassing the need for a second surgery. Moreover, increasing installations of surgical robots such as the da Vinci Surgical System in hospital settings and rising efforts to lower the work burden on surgeons and co-workers are factors driving segment growth. This robotic-assisted system can be used for various minimally invasive gynecologic procedures, including hysteroscopic myomectomies, polypectomies, endometrial ablation, or other associated conditions. Therefore, the number of patients preferring noninvasive treatment is expected to significantly increase the adoption of gynecology robotic surgeries in hospitals.
An increasing number of specialty clinics, especially for women's health treatment, and the consequent rise in surgical procedures will likely boost segment growth during the forecast period. For instance, in June 2015, Sakra World Hospital launched Sakra Hysteroscopy Clinic, a joint venture among SECOM Hospitals of Japan, Toyota Tsuho Corporation, and Kirloskar. This clinic was established to conduct diagnostic tests and minimally invasive procedures for abnormal uterine bleeding and treatment for polyps, fibroids, miscarriages, and endometrial ablation. Similarly, a collaborative hysteroscopy clinic was launched in 2015 by Mayo Clinic to improve the management of patients with abnormal uterine bleeding and the use of hysteroscopy in a general gynecology practice setting. Thus, increasing hysteroscopes for abnormal uterine bleeding, fertility examinations, and transcervical sterilizations is responsible for segment growth.
Outpatient (ambulatory) hysteroscopy is performed in an appropriately equipped and staffed treatment room outside of the formal setting of an operating room. This provides patient comfort and decreases diagnostic hysteroscopy time requirements. Due to the setup's inclusion of an examination room and lack of the need for an additional operating suite, it is also practical and affordable for both patients and surgeons. Furthermore, recent advancements in technology and instrumentation, like the use of integrated, portable, battery-operated imaging and bettering pain management to make hysteroscopy less painful and invasive, make it simple to perform procedures in ambulatory settings.
Most hospitals now provide ambulatory diagnostic hysteroscopy services to aid in managing abnormal uterine bleeding or to remove a polyp seen on a scan. Therefore, such see-and-treat approaches have shifted gynecological procedures from inpatient to outpatient. Increasing reimbursement for ambulatory hysteroscopy procedures, combined with the proliferation of ambulatory surgery centers, encourages patients to seek care at these facilities.
Based on region, the global hysteroscopy procedures market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America is the most significant global hysteroscopy procedures market shareholder and is anticipated to exhibit a CAGR of 6.6% during the forecast period. The existence of important market players, increasing product approval and commercialization, and increased awareness regarding the accessibility of diagnostic tests and treatments all contributed to the expansion of the North American market. Moreover, increasing investments in gynecological system R&D and surging demand for minimally invasive procedures are among the factors driving market expansion in the area. For instance, the Luminelle DTx Hysteroscopy System by UVision360 was given FDA approval in August 2018 for both hysteroscopy and cystoscopy. The system enables medical professionals to conduct hysteroscopic procedures in-office, such as biopsies, and find abnormal tissue growth. As a result, strong distribution channels, easy access to healthcare technologies, and competition among major players regarding product innovation all contribute to the market growth in this area.
Europe is predicted to exhibit a CAGR of 6.02% over the forecast period. Europe accounted for the second most significant market share of the hysteroscopy procedures market after North America and is anticipated to exhibit significant growth over the forecast period. This region is one of the most developed globally, with advanced technologies and infrastructure, resulting in many healthcare facilities and quality patient care. The increasing prevalence of disorders, such as uterine fibroids, polyps, cervical cancer, abnormal vaginal bleeding, the rising number of surgical procedures, various key players, and the introduction of cutting-edge products in Europe contribute to market growth. The high share of Europe's hysteroscopy procedures market is also attributed to factors such as high disposable income brought on by the existence of developed economies, the accessibility of well-established healthcare infrastructure, and the availability of skilled professionals.
The Asia-Pacific hysteroscopy procedures market will probably be driven by improving reimbursement scenarios, growing medical tourism, and advancing technology. Several factors, including the large patient base and the growing demand for technologically sophisticated and affordable healthcare solutions, are also anticipated to create significant growth opportunities in the market. The expansion of clinical trials and significant R&D expenditures by international market players to access underserved markets in the Asia-Pacific region are key market drivers with a significant impact. Additionally, it is anticipated that the number of surgeries and the incidence of diseases related to women's health will rise over the forecast period. Some of the Asia Pacific's emerging economies include Singapore and South Korea.
Latin America is estimated to develop significantly over the forecast period. Rapidly developing economies such as Brazil and Mexico are primarily driving the growth of the Latin American hysteroscopy procedures market. Geographical proximity to the U.S., increasing medical tourism from North America due to affordable healthcare facilities, rising prevalence of chronic diseases, and growing availability of new technologies are some of the major factors propelling the market growth. Moreover, the increasing incidence of gynecological disorders and the rising number of consequent surgeries fuel the market growth. In addition, governments of various nations in the region are striving to improve healthcare infrastructure. Hence, an increase in the number of patients seeking safer healthcare solutions is likely to drive the hysteroscopy procedures market in the region.
The Middle East and Africa hysteroscopy procedures market is predicted to develop substantially over the forecast period due to the growing regional healthcare expenditure. In Middle Eastern countries, government organizations cover almost 70% of the healthcare expenditure for citizens. High-income countries, such as Saudi Arabia, Israel, and Qatar, are focused on adopting the latest devices in their healthcare systems. In addition, growing health insurance penetration and increasing regional disease burden in these countries are expected to drive market growth. According to the latest data from International Agency for Research on Cancer (IARC), published in the Global Cancer Observatory, over 7,600 women in the MENA region died from cervical cancer in 2018. Therefore, government efforts and developing healthcare infrastructure in the region are expected to further fuel market growth.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
"Find new revenue generation opportunities"